{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:29:42Z","timestamp":1793982582332,"version":"4.8.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-025-04080-9","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T13:52:42Z","timestamp":1743083562000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Ten tips for managing complement-mediated thrombotic microangiopathies (formerly atypical hemolytic uremic syndrome): narrative review"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2455-0668","authenticated-orcid":false,"given":"Pilar","family":"Musalem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"4080_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fr\u00e9meaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390:681\u201396.","journal-title":"Lancet"},{"key":"4080_CR2","doi-asserted-by":"crossref","unstructured":"Alconcher LF, Coccia PA, Suarez A del, Monteverde C, Guti\u00e9rrez ML, Carlopio MGP et al. PM,. Hyponatremia: a new predictor of mortality in patients with Shiga toxin-producing Escherichia coli hemolytic uremic syndrome. Pediatr Nephrol. 2018;33:1791\u20138.","DOI":"10.1007\/s00467-018-3991-6"},{"key":"4080_CR3","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s00467-022-05851-4","volume":"38","author":"LF Alconcher","year":"2023","unstructured":"Alconcher LF, Lucarelli LI, Bronfen S. Long-term kidney outcomes in non-dialyzed children with Shiga-toxin Escherichia coli associated hemolytic uremic syndrome. Pediatr Nephrol. 2023;38:2131\u20136.","journal-title":"Pediatr Nephrol"},{"key":"4080_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1106920","volume":"365","author":"A RD","year":"2011","unstructured":"RD A, WD R, Ali WSJ, Nadia B, Flemming B. Origins of the E. coli strain causing an outbreak of Hemolytic\u2013Uremic syndrome in Germany. N Engl J Med. 2011;365:709\u201317.","journal-title":"N Engl J Med"},{"key":"4080_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1681\/ASN.2004100861","volume":"16","author":"M Noris","year":"2005","unstructured":"Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16:1035\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"4080_CR6","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.kint.2024.05.021","volume":"106","author":"CM Nester","year":"2024","unstructured":"Nester CM, Feldman DL, Burwick R, Cataland S, Chaturvedi S, Cook HT, et al. An expert discussion on the atypical hemolytic uremic syndrome nomenclature\u2014identifying a road map to precision: a report of a National kidney foundation working group. Kidney Int. 2024;106:326\u201336.","journal-title":"Kidney Int"},{"key":"4080_CR7","doi-asserted-by":"publisher","unstructured":"Kavanagh D, Ardissino G, Brocklebank V, Bouwmeester RN, Bagga A, Heine R et al. ter,. Outcomes from the International Society of Nephrology Haemolytic Uraemic Syndromes International Forum. Kidney Int. 2024. https:\/\/doi.org\/10.1016\/j.kint.2024.09.012","DOI":"10.1016\/j.kint.2024.09.012"},{"key":"4080_CR8","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1002\/ajh.26854","volume":"98","author":"J Leon","year":"2023","unstructured":"Leon J, LeStang M, Sberro-Soussan R, Servais A, Anglicheau D, Fr\u00e9meaux\u2010Bacchi V, et al. Complement\u2010driven hemolytic uremic syndrome. Am J Hematol. 2023;98:S44\u201356.","journal-title":"Am J Hematol"},{"key":"4080_CR9","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1053\/j.ajkd.2022.10.014","volume":"81","author":"DS Genest","year":"2023","unstructured":"Genest DS, Patriquin CJ, Licht C, John R, Reich HN. Renal thrombotic microangiopathy: A review. Am J Kidney Dis. 2023;81:591\u2013605.","journal-title":"Am J Kidney Dis"},{"key":"4080_CR10","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1182\/blood-2007-09-109876","volume":"111","author":"M J\u00f3zsi","year":"2008","unstructured":"J\u00f3zsi M, Licht C, Strobel S, Zipfel SLH, Richter H, Heinen S, et al. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1\/CFHR3 deficiency. Blood. 2008;111:1512\u20134.","journal-title":"Blood"},{"key":"4080_CR11","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH LEE","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res. 2009;66:336\u201340.","journal-title":"Pediatr Res"},{"key":"4080_CR12","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:654\u201366.","journal-title":"N Engl J Med"},{"key":"4080_CR13","first-page":"205435812110087","volume":"8","author":"PA McFarlane","year":"2021","unstructured":"McFarlane PA, Bitzan M, Broome C, Baran D, Garland J, Girard L-P, et al. Making the correct diagnosis in thrombotic microangiopathy: A narrative review. Can J Kidney Heal Dis. 2021;8:20543581211008708.","journal-title":"Can J Kidney Heal Dis"},{"key":"4080_CR14","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1007\/s00467-007-0518-y","volume":"23","author":"L Copelovitch","year":"2008","unstructured":"Copelovitch L, Kaplan BS. Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2008;23:1951\u20136.","journal-title":"Pediatr Nephrol"},{"key":"4080_CR15","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/pathogens10060727","volume":"10","author":"HS Agarwal","year":"2021","unstructured":"Agarwal HS, Latifi SQ. Streptococcus Pneumoniae-Associated hemolytic uremic syndrome in the era of Pneumococcal vaccine. Pathogens. 2021;10:727.","journal-title":"Pathogens"},{"key":"4080_CR16","doi-asserted-by":"publisher","first-page":"e10208","DOI":"10.1371\/journal.pone.0010208","volume":"5","author":"P Coppo","year":"2010","unstructured":"Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, et al. Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE. 2010;5:e10208.","journal-title":"PLoS ONE"},{"key":"4080_CR17","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3389\/fped.2014.00097","volume":"2","author":"J Hofer","year":"2014","unstructured":"Hofer J, Rosales A, Fischer C, Giner T. Extra-Renal manifestations of Complement-Mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97.","journal-title":"Front Pediatr"},{"key":"4080_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s12882-015-0195-1","volume":"16","author":"C Licht","year":"2015","unstructured":"Licht C, Ardissino G, Ariceta G, Cohen D, Cole JA, Gasteyger C, et al. The global aHUS registry: methodology and initial patient characteristics. BMC Nephrol. 2015;16:207.","journal-title":"BMC Nephrol"},{"key":"4080_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s11239-021-02431-5","volume":"51","author":"EL Weil","year":"2021","unstructured":"Weil EL, Rabinstein AA. Neurological manifestations of thrombotic microangiopathy syndromes in adult patients. J Thromb Thrombolysis. 2021;51:1163\u20139.","journal-title":"J Thromb Thrombolysis"},{"key":"4080_CR20","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.kint.2024.02.014","volume":"105","author":"V Maisons","year":"2024","unstructured":"Maisons V, Duval A, Mesnard L, Frimat M, Fakhouri F, Grang\u00e9 S, et al. Assessment of epidemiology and outcomes of adult patients with kidney-limited thrombotic microangiopathies. Kidney Int. 2024;105:1100\u201312.","journal-title":"Kidney Int"},{"key":"4080_CR21","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.modpat.2024.100690","volume":"38","author":"DPC van Doorn","year":"2025","unstructured":"van Doorn DPC, Tobal R, Abdul-Hamid MA, van Paassen P, Timmermans SAMEG. Etiology and outcomes of Kidney-Limited and systemic thrombotic microangiopathy. Mod Pathol. 2025;38:100690.","journal-title":"Mod Pathol"},{"key":"4080_CR22","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","volume":"4","author":"PK Bendapudi","year":"2017","unstructured":"Bendapudi PK, Hurwitz S, Fry A, Marques MB, Waldo SW, Li A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4:e157\u201364.","journal-title":"Lancet Haematol"},{"key":"4080_CR23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","volume":"18","author":"XL Zheng","year":"2020","unstructured":"Zheng XL, Vesely SK, Cataland SR, Coppo P, Geldziler B, Iorio A, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18:2496\u2013502.","journal-title":"J Thromb Haemost"},{"key":"4080_CR24","doi-asserted-by":"crossref","unstructured":"Rairikar M, Sartain SE, Solomon C, Hui S-KR, Srivaths P. Plasmic (PLASMICkid) Score for Pediatric Thrombotic Thrombocytopenic Purpura. Blood. 2022;140 Supplement 1:11346\u20137.","DOI":"10.1182\/blood-2022-170608"},{"key":"4080_CR25","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1542\/peds.100.1.e12","volume":"100","author":"BP Bell","year":"1997","unstructured":"Bell BP, Griffin PM, Lozano P, Christie DL, Kobayashi JM, Tarr PI. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics. 1997;100:e12\u201312.","journal-title":"Pediatrics"},{"key":"4080_CR26","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1128\/JCM.00115-15","volume":"53","author":"X Qin","year":"2015","unstructured":"Qin X, Klein EJ, Galanakis E, Thomas AA, Stapp JR, Rich S, et al. Real-Time PCR assay for detection and differentiation of Shiga Toxin-Producing Escherichia coli from clinical samples. J Clin Microbiol. 2015;53:2148\u201353.","journal-title":"J Clin Microbiol"},{"key":"4080_CR27","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1056\/NEJMcp1901117","volume":"381","author":"AJ Peixoto","year":"2019","unstructured":"Peixoto AJ. Acute severe hypertension. N Engl J Med. 2019;381:1843\u201352.","journal-title":"N Engl J Med"},{"key":"4080_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0140-6736(00)02539-3","volume":"356","author":"CJ Vaughan","year":"2000","unstructured":"Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411\u20137.","journal-title":"Lancet"},{"key":"4080_CR29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1093\/ndt\/gfac248","volume":"38","author":"T Cavero","year":"2022","unstructured":"Cavero T, Au\u00f1\u00f3n P, Caravaca-Font\u00e1n F, Trujillo H, Arjona E, Morales E, et al. Thrombotic microangiopathy in patients with malignant hypertension. Nephrol Dial Transpl. 2022;38:1217\u201326.","journal-title":"Nephrol Dial Transpl"},{"key":"4080_CR30","doi-asserted-by":"crossref","unstructured":"Musalem P, Pedreros-Rosales C, M\u00fcller-Ortiz H, Gutierrez-Navarro C, Carpio JD. Complement-Mediated thrombotic microangiopathy after kidney transplant: should treatment with C5 inhibitor be lifelong? Nephron. 2024:1\u20135.","DOI":"10.1159\/000538826"},{"key":"4080_CR31","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","volume":"56","author":"JA Young","year":"2021","unstructured":"Young JA, Pallas CR, Knovich MA. Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis. Bone Marrow Transpl. 2021;56:1805\u201317.","journal-title":"Bone Marrow Transpl"},{"key":"4080_CR32","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.kint.2019.07.006","volume":"96","author":"F Caravaca-Fontan","year":"2019","unstructured":"Caravaca-Fontan F, Praga M. Complement inhibitors are useful in secondary hemolytic uremic syndromes. Kidney Int. 2019;96:826\u20139.","journal-title":"Kidney Int"},{"key":"4080_CR33","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1097\/01.AOG.0000126245.35811.2a","volume":"103","author":"BM Sibai","year":"2004","unstructured":"Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981\u201391.","journal-title":"Obstet Gynecol"},{"key":"4080_CR34","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.transci.2016.04.009","volume":"54","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F. Pregnancy-related thrombotic microangiopathies: clues from complement biology. Transfus Apher Sci. 2016;54:199\u2013202.","journal-title":"Transfus Apher Sci"},{"key":"4080_CR35","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2215\/CJN.00280117","volume":"12","author":"A Bruel","year":"2017","unstructured":"Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12:1237\u201347.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4080_CR36","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1161\/HYPERTENSIONAHA.121.17311","volume":"78","author":"RM Burwick","year":"2021","unstructured":"Burwick RM, Moyle K, Java A, Gupta M, Differentiating Hemolysis. Elevated liver enzymes, and low platelet count syndrome and atypical hemolytic uremic syndrome in the postpartum period. Hypertension. 2021;78:760\u20138.","journal-title":"Hypertension"},{"key":"4080_CR37","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1182\/blood-2015-08-663435","volume":"127","author":"S Jodele","year":"2016","unstructured":"Jodele S, Zhang K, Zou F, Laskin B, Dandoy CE, Myers KC, et al. The genetic fingerprint of susceptibility for transplant-associated thrombotic microangiopathy. Blood. 2016;127:989\u201396.","journal-title":"Blood"},{"key":"4080_CR38","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/nep.14304","volume":"29","author":"C Licht","year":"2024","unstructured":"Licht C, Al-Dakkak I, Anokhina K, Isbel N, Fr\u00e9meaux\u2010Bacchi V, Gilbert RD, et al. Characterization of patients with aHUS and associated triggers or clinical conditions: A global aHUS registry analysis. Nephrology. 2024;29:519\u201327.","journal-title":"Nephrology"},{"key":"4080_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2215\/CJN.0000000000000182","volume":"18","author":"A Werion","year":"2023","unstructured":"Werion A, Storms P, Zizi Y, Beguin C, Bernards J, Cambier J-F, et al. Epidemiology, outcomes, and complement gene variants in secondary thrombotic microangiopathies. Clin J Am Soc Nephrol. 2023;18:881\u201391.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4080_CR40","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V. Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol. 2021;17:543\u201353.","journal-title":"Nat Rev Nephrol"},{"key":"4080_CR41","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.kint.2024.05.015","volume":"106","author":"M Vivarelli","year":"2024","unstructured":"Vivarelli M, Barratt J, Beck LH, Fakhouri F, Gale DP, de Jorge EG, et al. The role of complement in kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int. 2024;106:369\u201391.","journal-title":"Kidney Int"},{"key":"4080_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaim\u00e9 F, Dragon-Durey M-A, Ngo S, et al. Genetics and outcome of atypical hemolytic uremic syndrome: A nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4080_CR43","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, et al. Relative role of genetic complement abnormalities in sporadic and Familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4080_CR44","unstructured":"C L, K D PMCL. M H, Y D, et al. A phase II study of Eculizumab in patients with atypical hemolytic uremic syndrome receiving chronic plasma exchange\/infusion: interim analysis. 16th Congress of the European Hematology Association. 2011."},{"key":"4080_CR45","unstructured":"Loirat C, Babu S, Furman R, Sheerin N, Cohen D, Gaber O et al. Eculizumab efficacy and safety in patients with atypical hemolytic uremic syndrome resistant to plasma exchange\/infusion. 16th Congress Eur Hematol Association. 2011."},{"key":"4080_CR46","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM L","year":"2013","unstructured":"L CM, L C, L.A. G PM. Terminal complement inhibitor Eculizumab in atypical Hemolytic\u2013Uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"},{"key":"4080_CR47","doi-asserted-by":"publisher","first-page":"e0195909","DOI":"10.1371\/journal.pone.0195909","volume":"13","author":"D Sheridan","year":"2018","unstructured":"Sheridan D, Yu Z-X, Zhang Y, Patel R, Sun F, Lasaro MA, et al. Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action. PLoS ONE. 2018;13:e0195909.","journal-title":"PLoS ONE"},{"key":"4080_CR48","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.kint.2020.01.035","volume":"97","author":"E Rondeau","year":"2020","unstructured":"Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome Na\u00efve to complement inhibitor treatment. Kidney Int. 2020;97:1287\u201396.","journal-title":"Kidney Int"},{"key":"4080_CR49","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.kint.2020.10.046","volume":"100","author":"G Ariceta","year":"2021","unstructured":"Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, et al. The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome Na\u00efve to complement inhibitor treatment. Kidney Int. 2021;100:225\u201337.","journal-title":"Kidney Int"},{"key":"4080_CR50","doi-asserted-by":"publisher","first-page":"100855","DOI":"10.1016\/j.xkme.2024.100855","volume":"6","author":"BP Dixon","year":"2024","unstructured":"Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, et al. Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-Year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med. 2024;6:100855.","journal-title":"Kidney Med"},{"key":"4080_CR51","doi-asserted-by":"publisher","first-page":"2648","DOI":"10.1016\/j.ekir.2024.06.020","volume":"9","author":"F Schaefer","year":"2024","unstructured":"Schaefer F, Al-Dakkak I, Anokhina K, Cohen D, Greenbaum LA, Ariceta G. Global aHUS registry analysis of patients switching to ravulizumab from Eculizumab. Kidney Int Rep. 2024;9:2648\u201356.","journal-title":"Kidney Int Rep"},{"key":"4080_CR52","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1186\/s12882-024-03638-3","volume":"25","author":"K Sch\u00f6nfelder","year":"2024","unstructured":"Sch\u00f6nfelder K, K\u00fchne L, Schulte-Kemna L, Kaufeld J, Rohn H, Kribben A, et al. Clinical efficacy and safety of switching from Eculizumab to ravulizumab in adult patients with aHUS\u2013 real-world data. BMC Nephrol. 2024;25:202.","journal-title":"BMC Nephrol"},{"key":"4080_CR53","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4161\/viru.26515","volume":"5","author":"LA Lewis","year":"2014","unstructured":"Lewis LA, Ram S. Meningococcal disease and the complement system. Virulence. 2014;5:98\u2013126.","journal-title":"Virulence"},{"key":"4080_CR54","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jinf.2018.10.015","volume":"78","author":"PE Crew","year":"2019","unstructured":"Crew PE, McNamara L, Waldron PE, McCulley L, Jones SC, Bersoff-Matcha SJ. Unusual neisseria species as a cause of infection in patients taking Eculizumab. J Infect. 2019;78:113\u20138.","journal-title":"J Infect"},{"key":"4080_CR55","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1093\/jpids\/pix066","volume":"6","author":"ST O\u2019Leary","year":"2017","unstructured":"O\u2019Leary ST, Kimberlin DW. Update from the advisory committee on immunization practices. J Pediatr Infect Dis Soc. 2017;6:311\u20136.","journal-title":"J Pediatr Infect Dis Soc"},{"key":"4080_CR56","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00277-017-2924-y","volume":"96","author":"F Alashkar","year":"2017","unstructured":"Alashkar F, Vance C, Herich-Terh\u00fcrne D, Preising N, D\u00fchrsen U, R\u00f6th A. Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor Eculizumab. Ann Hematol. 2017;96:589\u201396.","journal-title":"Ann Hematol"},{"key":"4080_CR57","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1182\/bloodadvances.2020002497","volume":"4","author":"JD Langereis","year":"2020","unstructured":"Langereis JD, Broek B, van den, Franssen S, Joosten I, Blijlevens NMA, de Jonge MI, et al. Eculizumab impairs neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients. Blood Adv. 2020;4:3615\u201320.","journal-title":"Blood Adv"},{"key":"4080_CR58","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving Eculizumab (Soliris) despite receipt of meningococcal vaccine. Morb Mortal Wkly Rep. 2017;66:734\u20137.","journal-title":"Morb Mortal Wkly Rep"},{"key":"4080_CR59","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.kint.2018.02.029","volume":"94","author":"F Schaefer","year":"2018","unstructured":"Schaefer F, Ardissino G, Ariceta G, Fakhouri F, Scully M, Isbel N, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94:408\u201318.","journal-title":"Kidney Int"},{"key":"4080_CR60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.thromres.2020.06.016","volume":"194","author":"JW Yun","year":"2020","unstructured":"Yun JW, Oh J, Lee K-O, Lee SJ, Kim JO, Kim NK, et al. Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. Thromb Res. 2020;194:45\u201353.","journal-title":"Thromb Res"},{"key":"4080_CR61","doi-asserted-by":"publisher","first-page":"CJN11830720","DOI":"10.2215\/CJN.11830720","volume":"16","author":"M Lemaire","year":"2021","unstructured":"Lemaire M, Noone D, Lapeyraque A-L, Licht C. Fr\u00e9meaux-Bacchi V. Inherited kidney complement diseases. Clin J Am Soc Nephrol. 2021;16:CJN11830720.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4080_CR62","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, et al. Genetic analysis of 400 patients refines Understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29:2809\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"4080_CR63","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2022.02.006","volume":"24","author":"N Tschernoster","year":"2022","unstructured":"Tschernoster N, Erger F, Walsh PR, McNicholas B, Fistrek M, Habbig S, et al. Unraveling structural rearrangements of the CFH gene cluster in atypical hemolytic uremic syndrome patients using molecular combing and Long-Fragment targeted sequencing. J Mol Diagn. 2022;24:619\u201331.","journal-title":"J Mol Diagn"},{"key":"4080_CR64","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.1182\/blood.2020009280","volume":"137","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fila M, Hummel A, Ribes D, Sellier-Leclerc A-L, Ville S, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137:2438\u201349.","journal-title":"Blood"},{"key":"4080_CR65","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1182\/bloodadvances.2020003175","volume":"5","author":"S Chaturvedi","year":"2021","unstructured":"Chaturvedi S, Dhaliwal N, Hussain S, Dane K, Upreti H, Braunstein EM, et al. Outcomes of a clinician-directed protocol for discontinuation of complement Inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021;5:1504\u201312.","journal-title":"Blood Adv"},{"key":"4080_CR66","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ekir.2022.10.013","volume":"8","author":"RN Bouwmeester","year":"2023","unstructured":"Bouwmeester RN, Duineveld C, Wijnsma KL, Bemelman FJ, Heijden JW, van van der, Wijk JAE, et al. Early Eculizumab withdrawal in patients with atypical hemolytic uremic syndrome in native kidneys is safe and Cost-Effective: results of the CUREiHUS study. Kidney Int Rep. 2023;8:91\u2013102.","journal-title":"Kidney Int Rep"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04080-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04080-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T18:56:48Z","timestamp":1743361008000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04080-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4080"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04080-9","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"158"}}